Overview

A Global Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain

Status:
Completed
Trial end date:
2016-12-19
Target enrollment:
Participant gender:
Summary
A randomized study evaluating the safety and efficacy of elagolix in the management of moderate to severe endometriosis-associated pain in adult premenopausal female subjects.
Phase:
Phase 3
Details
Lead Sponsor:
AbbVie